COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®
Formycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE®. Approval for treating retinal diseases granted by UK's MHRA -
-
COMMUNIQUÉ DE PRESSE
UniDoc - Announces Filing of Amended and Restated Interim Management Discussion and Analysis
UniDoc Health Corp. issues amended and restated management's discussion and analysis for clarifying disclosure following continuous disclosure review by the British Columbia Securities Commission -
-
COMMUNIQUÉ DE PRESSE
Onco-Innovations' PKNP Technology Shown in Study to Demonstrate Low Toxicity and High Safety Profile
Onco-Innovations Limited announces successful preclinical study results of its second-generation nanoparticle formulation of PNKP Compound, showing enhanced inhibitor delivery with minimal toxicity for potential cancer therapy -
COMMUNIQUÉ DE PRESSE
Kingstone Announces Record Operating Profit and Growth for Fourth Quarter and Full Year 2024
Kingstone Companies, Inc. schedules conference call on March 14 for fourth quarter 2024 financial results. Company's preliminary financial performance highlights significant improvements in direct written premiums and operating income -
COMMUNIQUÉ DE PRESSE
Sanofi : Déclaration des transactions sur actions propres
-
COMMUNIQUÉ DE PRESSE
Sanofi: Disclosure of trading in own shares
-
